Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics Reports Q3 2026 Revenue of $832.5 Million and Net Income of $258.6 Million

Mixed Impact 3 of 5 earnings

United Therapeutics Corporation reported third-quarter 2026 total revenues of $832.5 million, a 4% increase year-over-year, driven by higher sales of Tyvaso DPI and Orenitram. However, net income decreased to $258.6 million, down from $338.7 million in the third quarter of 2025, largely due to increased research and development expenses associated with the Thymmune acquisition.

Key points

  • Total revenues for the quarter ended September 30, 2026, rose 4% to $832.5 million compared to $799.5 million for the same period in 2025.
  • Net income declined 24% to $258.6 million, or $5.71 per diluted share, compared to $338.7 million, or $7.16 per diluted share, in the third quarter of 2025.
  • Research and development expenses increased 119% to $279.2 million, driven by the acquisition of Thymmune Therapeutics, Inc. and ongoing organ alternative projects.
  • The board approved a new share repurchase program in October 2026 authorizing up to $2.0 billion in aggregate repurchases through October 21, 2027.

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECNov 4, 2026, 6:31 AM ET
Accession number0001082554-26-000036

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 4, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.